Vanguard Group Inc. Purchases 43,355 Shares of KalVista Pharmaceuticals, Inc. $KALV

Key Points

• Vanguard Group Inc. increased its stake in KalVista Pharmaceuticals by 1.9%, owning 2,298,598 shares valued at approximately $26.5 million as of the latest SEC filing.
• KalVista Pharmaceuticals reported a significant earnings miss, with an EPS of ($3.69), falling short of analyst estimates by ($2.86).
• Several brokerages raised their price targets for KalVista, with HC Wainwright setting a new target of $27.00 and maintaining a "buy" rating.

Vanguard Group Inc. raised its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 1.9% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,298,598 shares of the specialty pharmaceutical company's stock after acquiring an additional 43,355 shares during the period. Vanguard Group Inc. owned approximately 4.62% of KalVista Pharmaceuticals worth $26,526,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of KALV. Boxer Capital Management LLC purchased a new position in shares of KalVista Pharmaceuticals during the 4th quarter valued at about $13,467,000. Octagon Capital Advisors LP purchased a new position in shares of KalVista Pharmaceuticals during the 4th quarter valued at about $11,604,000. Frazier Life Sciences Management L.P. raised its holdings in shares of KalVista Pharmaceuticals by 32.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company's stock valued at $41,400,000 after buying an additional 1,200,000 shares in the last quarter. Stempoint Capital LP purchased a new position in shares of KalVista Pharmaceuticals during the 4th quarter valued at about $8,409,000. Finally, Vestal Point Capital LP raised its holdings in shares of KalVista Pharmaceuticals by 19.3% during the 4th quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company's stock valued at $40,402,000 after buying an additional 770,000 shares in the last quarter.

KalVista Pharmaceuticals Stock Performance

KALV traded down $0.05 on Monday, hitting $13.46. 436,472 shares of the company were exchanged, compared to its average volume of 635,500. The firm has a fifty day simple moving average of $13.50 and a two-hundred day simple moving average of $12.50. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.30 and a 12 month high of $16.32. The stock has a market capitalization of $677.58 million, a PE ratio of -3.65 and a beta of -0.10.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its quarterly earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($2.86). During the same period last year, the company posted ($1.07) earnings per share. On average, equities analysts expect that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Benjamin L. Palleiko sold 10,940 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.22, for a total value of $144,626.80. Following the sale, the chief executive officer directly owned 386,858 shares in the company, valued at approximately $5,114,262.76. This trade represents a 2.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Paul K. Audhya sold 2,336 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $13.42, for a total value of $31,349.12. Following the completion of the sale, the insider owned 122,505 shares in the company, valued at approximately $1,644,017.10. This represents a 1.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 59,710 shares of company stock worth $880,764. Corporate insiders own 4.30% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on KALV shares. JMP Securities raised their price objective on KalVista Pharmaceuticals from $19.00 to $27.00 and gave the company a "market outperform" rating in a report on Tuesday, July 8th. HC Wainwright raised their price objective on KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. Finally, Leerink Partners raised their price objective on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an "outperform" rating in a report on Monday, July 7th. One analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the stock. According to data from MarketBeat, KalVista Pharmaceuticals currently has a consensus rating of "Buy" and a consensus target price of $26.29.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).